ADMA Biologics (ADMA) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

ADMA Stock Forecast

ADMA Biologics stock forecast is as follows: an average price target of $16.00 (represents a -26.54% downside from ADMA’s last price of $21.78) and a rating consensus of 'Strong Buy', based on 2 wall street analysts offering a 1-year stock forecast.

ADMA Price Target

The average price target for ADMA Biologics (ADMA) is $16.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $18.00 to $14.00. This represents a potential -26.54% downside from ADMA's last price of $21.78.

ADMA Analyst Ratings

Strong Buy

According to 2 Wall Street analysts, ADMA Biologics's rating consensus is 'Strong Buy'. The analyst rating breakdown for ADMA stock is 1 'Strong Buy' (50.00%), 1 'Buy' (50.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ADMA Biologics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 14, 2024	Raghuram Selvaraju	H.C. Wainwright	$18.00	$17.14	4.99%	-17.36%
Jun 20, 2024	Anthony Petrone	Mizuho Securities	$14.00	$10.62	31.83%	-35.72%
Jan 03, 2023	-	H.C. Wainwright	$4.50	$3.88	15.98%	-79.34%
Nov 10, 2022	-	Mizuho Securities	$6.00	$3.05	96.68%	-72.45%
Jul 25, 2022	-	H.C. Wainwright	$4.00	$2.17	84.33%	-81.63%

Row per page

Go to

The latest ADMA Biologics stock forecast, released on Oct 14, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $18.00, which represents a 4.99% increase from the stock price at the time of the forecast ($17.14), and a -17.36% decrease from ADMA last price ($21.78).

ADMA Biologics Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	2
Avg Price Target	$18.00	$18.00	$16.00
Last Closing Price	$21.78	$21.78	$21.78
Upside/Downside	-17.36%	-17.36%	-26.54%

In the current month, the average price target of ADMA Biologics stock is $18.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a -17.36% decrease as opposed to ADMA Biologics's last price of $21.78. This month's average price target is down 0.00% compared to last quarter, and up 12.50% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 14, 2024	Cantor Fitzgerald	Underperform	Underperform	Hold
Oct 14, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 20, 2024	Cantor Fitzgerald	Buy	Buy	Hold
Aug 12, 2024	H.C. Wainwright	Buy	Buy	Hold
Jul 09, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
May 10, 2024	Raymond James	Strong Buy	Strong Buy	Hold
May 10, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
May 10, 2024	H.C. Wainwright	Buy	Buy	Hold
Feb 29, 2024	Cantor Fitzgerald	Underperform	Underperform	Hold
Feb 29, 2024	H.C. Wainwright	Buy	Buy	Hold

Row per page

Go to

ADMA Biologics's last stock rating was published by Cantor Fitzgerald on Oct 14, 2024. The company gave ADMA a "Underperform" rating, the same as its previous rate.

ADMA Biologics Financial Forecast

ADMA Biologics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
Revenue	-	-	-	-	-	-	-	-	-	$67.27M	$60.12M	$56.91M	$49.98M	$41.09M	$33.91M	$29.10M	$26.38M	$20.68M	$17.83M	$16.05M	$13.96M	$10.28M	$7.79M	$10.20M	$12.04M	$7.22M	$6.56M	$3.53M	$4.04M	$2.63M
Avg Forecast	$129.35M	$125.10M	$117.13M	$112.80M	$113.38M	$105.81M	$86.44M	$77.28M	$72.13M	$62.13M	$55.50M	$51.26M	$46.35M	$34.48M	$31.81M	$25.90M	$21.76M	$18.70M	$16.42M	$14.58M	$12.85M	$9.96M	$10.57M	$11.34M	$10.42M	$5.77M	$4.08M	$3.48M	$3.21M	$2.61M
High Forecast	$134.52M	$130.10M	$121.81M	$113.41M	$116.33M	$105.83M	$86.44M	$80.36M	$75.01M	$64.61M	$57.72M	$53.31M	$48.21M	$34.48M	$31.81M	$25.90M	$21.76M	$18.70M	$16.42M	$14.58M	$12.85M	$9.96M	$10.57M	$11.34M	$10.42M	$5.77M	$4.08M	$3.48M	$3.86M	$3.14M
Low Forecast	$126.10M	$121.96M	$114.18M	$112.19M	$110.42M	$105.80M	$86.44M	$75.33M	$70.31M	$60.56M	$54.11M	$49.97M	$45.19M	$34.48M	$31.81M	$25.90M	$21.76M	$18.70M	$16.42M	$14.58M	$12.85M	$9.96M	$10.57M	$11.34M	$10.42M	$5.77M	$4.08M	$3.48M	$2.57M	$2.09M
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5	5	5	12	9
Surprise %	-	-	-	-	-	-	-	-	-	1.08%	1.08%	1.11%	1.08%	1.19%	1.07%	1.12%	1.21%	1.11%	1.09%	1.10%	1.09%	1.03%	0.74%	0.90%	1.15%	1.25%	1.61%	1.01%	1.26%	1.01%

ADMA Biologics's average Quarter revenue forecast for Dec 23 based on 2 analysts is $72.13M, with a low forecast of $70.31M, and a high forecast of $75.01M. ADMA's average Quarter revenue forecast represents a 7.21% increase compared to the company's last Quarter revenue of $67.27M (Sep 23).

ADMA Biologics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5	5	5	12	9
EBITDA	-	-	-	-	-	-	-	-	-	$8.69M	$2.03M	$-494.49K	$-6.32M	$-7.46M	$-7.47M	$-13.36M	$-11.82M	$-12.99M	$-14.33M	$-13.95M	$-15.07M	$-12.79M	$-16.23M	$-15.74M	$-7.00M	$-7.97M	$-10.33M	$-10.72M	$-15.67M	$-5.80M
Avg Forecast	$-73.82M	$-71.40M	$-66.85M	$-64.38M	$-64.71M	$-60.39M	$-49.33M	$-7.22M	$-41.16M	$-35.46M	$-31.68M	$-7.72M	$-3.23M	$-19.68M	$-18.16M	$-8.26M	$-12.42M	$-10.67M	$-9.37M	$-14.78M	$-7.33M	$-5.69M	$-6.03M	$-14.52M	$-5.95M	$-3.29M	$-2.33M	$-12.06M	$-11.63M	$-5.77M
High Forecast	$-71.97M	$-69.60M	$-65.17M	$-64.03M	$-63.02M	$-60.38M	$-49.33M	$-5.78M	$-40.13M	$-34.57M	$-30.88M	$-6.18M	$-2.58M	$-19.68M	$-18.16M	$-6.61M	$-12.42M	$-10.67M	$-9.37M	$-11.82M	$-7.33M	$-5.69M	$-6.03M	$-11.62M	$-5.95M	$-3.29M	$-2.33M	$-9.65M	$-9.30M	$-4.61M
Low Forecast	$-76.77M	$-74.25M	$-69.52M	$-64.73M	$-66.39M	$-60.40M	$-49.33M	$-8.67M	$-42.81M	$-36.87M	$-32.94M	$-9.27M	$-3.88M	$-19.68M	$-18.16M	$-9.91M	$-12.42M	$-10.67M	$-9.37M	$-17.73M	$-7.33M	$-5.69M	$-6.03M	$-17.42M	$-5.95M	$-3.29M	$-2.33M	$-14.47M	$-13.95M	$-6.92M
Surprise %	-	-	-	-	-	-	-	-	-	-0.24%	-0.06%	0.06%	1.95%	0.38%	0.41%	1.62%	0.95%	1.22%	1.53%	0.94%	2.05%	2.25%	2.69%	1.08%	1.18%	2.42%	4.44%	0.89%	1.35%	1.01%

2 analysts predict ADMA's average Quarter EBITDA for Dec 23 to be $-41.16M, with a high of $-40.13M and a low of $-42.81M. This is -573.96% lower than ADMA Biologics's previous annual EBITDA (Sep 23) of $8.69M.

ADMA Biologics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5	5	5	12	9
Net Income	-	-	-	-	-	-	-	-	-	$2.57M	$-6.37M	$-12.76M	$-25.93M	$-20.48M	$-18.36M	$-35.20M	$-20.11M	$-20.99M	$-22.23M	$-21.60M	$-21.60M	$-20.03M	$-23.23M	$-21.72M	$-13.30M	$-13.83M	$-15.09M	$-12.93M	$-19.11M	$-7.14M
Avg Forecast	$50.18M	$45.90M	$41.62M	$38.56M	$37.94M	$31.82M	$19.58M	$-9.02M	$6.12M	$-1.84M	$-6.12M	$-9.65M	$-3.86M	$-18.77M	$-19.37M	$-10.32M	$-22.45M	$-33.50M	$-36.93M	$-19.46M	$-39.96M	$-45.21M	$-38.02M	$-17.75M	$-42.08M	$-51.46M	$-67.51M	$-14.70M	$-13.22M	$-6.50M
High Forecast	$52.79M	$48.29M	$43.78M	$42.84M	$42.41M	$33.48M	$20.60M	$-7.21M	$9.18M	$-1.78M	$-5.92M	$-7.72M	$-3.09M	$-18.77M	$-19.37M	$-8.25M	$-22.45M	$-33.50M	$-36.93M	$-15.57M	$-39.96M	$-45.21M	$-38.02M	$-14.20M	$-42.08M	$-51.46M	$-67.51M	$-11.76M	$-10.58M	$-5.20M
Low Forecast	$48.54M	$44.40M	$40.26M	$32.13M	$33.48M	$30.78M	$18.94M	$-10.82M	$3.06M	$-1.93M	$-6.44M	$-11.57M	$-4.64M	$-18.77M	$-19.37M	$-12.38M	$-22.45M	$-33.50M	$-36.93M	$-23.35M	$-39.96M	$-45.21M	$-38.02M	$-21.31M	$-42.08M	$-51.46M	$-67.51M	$-17.64M	$-15.87M	$-7.80M
Surprise %	-	-	-	-	-	-	-	-	-	-1.40%	1.04%	1.32%	6.71%	1.09%	0.95%	3.41%	0.90%	0.63%	0.60%	1.11%	0.54%	0.44%	0.61%	1.22%	0.32%	0.27%	0.22%	0.88%	1.45%	1.10%

ADMA Biologics's average Quarter net income forecast for Dec 23 is $6.12M, with a range of $3.06M to $9.18M. ADMA's average Quarter net income forecast represents a 138.60% increase compared to the company's last Quarter net income of $2.57M (Sep 23).

ADMA Biologics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5	5	5	12	9
SG&A	-	-	-	-	-	-	-	-	-	$14.73M	$14.25M	$14.51M	$13.89M	$12.89M	$11.97M	$13.70M	$11.70M	$10.73M	$10.44M	$10.03M	$9.30M	$9.12M	$8.70M	$7.93M	$7.03M	$7.20M	$6.09M	$5.60M	$5.01M	$4.28M
Avg Forecast	$73.17M	$70.77M	$66.26M	$63.81M	$64.14M	$59.86M	$48.90M	$4.94M	$40.80M	$35.14M	$31.40M	$5.28M	$2.78M	$19.51M	$18.00M	$5.65M	$12.31M	$10.58M	$9.29M	$10.62M	$7.27M	$5.64M	$5.98M	$7.32M	$5.90M	$3.26M	$2.31M	$1.97M	$1.82M	$1.48M
High Forecast	$76.10M	$73.60M	$68.91M	$64.16M	$65.81M	$59.87M	$48.90M	$5.93M	$42.43M	$36.55M	$32.65M	$6.34M	$3.34M	$19.51M	$18.00M	$6.78M	$12.31M	$10.58M	$9.29M	$12.75M	$7.27M	$5.64M	$5.98M	$8.78M	$5.90M	$3.26M	$2.31M	$1.97M	$2.18M	$1.77M
Low Forecast	$71.34M	$68.99M	$64.59M	$63.47M	$62.47M	$59.85M	$48.90M	$3.95M	$39.78M	$34.26M	$30.61M	$4.23M	$2.23M	$19.51M	$18.00M	$4.52M	$12.31M	$10.58M	$9.29M	$8.50M	$7.27M	$5.64M	$5.98M	$5.85M	$5.90M	$3.26M	$2.31M	$1.97M	$1.45M	$1.18M
Surprise %	-	-	-	-	-	-	-	-	-	0.42%	0.45%	2.75%	4.99%	0.66%	0.67%	2.42%	0.95%	1.01%	1.12%	0.94%	1.28%	1.62%	1.45%	1.08%	1.19%	2.20%	2.64%	2.84%	2.75%	2.89%

ADMA Biologics's average Quarter SG&A projection for Dec 23 is $40.80M, based on 2 Wall Street analysts, with a range of $39.78M to $42.43M. The forecast indicates a 177.08% rise compared to ADMA last annual SG&A of $14.73M (Sep 23).

ADMA Biologics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17
# Analysts	1	1	1	2	3	1	1	1	2	1	1	1	1	1	1	1	1	1	1	1	9	9	9	9	5	5	5	5	12	9
EPS	-	-	-	-	-	-	-	-	-	$0.01	$-0.03	$-0.06	$-0.13	$-0.10	$-0.09	$-0.18	$-0.11	$-0.16	$-0.17	$-0.19	$-0.22	$-0.23	$-0.27	$-0.29	$-0.22	$-0.23	$-0.29	$-0.28	$-0.42	$-0.55
Avg Forecast	$0.20	$0.19	$0.17	$0.16	$0.15	$0.13	$0.08	$0.06	$0.03	$-0.01	$-0.03	$-0.04	$-0.07	$-0.08	$-0.08	$-0.09	$-0.09	$-0.14	$-0.15	$-0.17	$-0.17	$-0.19	$-0.16	$-0.11	$-0.17	$-0.21	$-0.28	$-0.29	$-0.23	$-0.28
High Forecast	$0.22	$0.20	$0.18	$0.17	$0.17	$0.14	$0.08	$0.06	$0.04	$-0.01	$-0.02	$-0.04	$-0.07	$-0.08	$-0.08	$-0.09	$-0.09	$-0.14	$-0.15	$-0.17	$-0.17	$-0.19	$-0.16	$-0.11	$-0.17	$-0.21	$-0.28	$-0.29	$-0.18	$-0.22
Low Forecast	$0.20	$0.18	$0.16	$0.13	$0.14	$0.13	$0.08	$0.05	$0.01	$-0.01	$-0.03	$-0.04	$-0.07	$-0.08	$-0.08	$-0.09	$-0.09	$-0.14	$-0.15	$-0.17	$-0.17	$-0.19	$-0.16	$-0.11	$-0.17	$-0.21	$-0.28	$-0.29	$-0.28	$-0.33
Surprise %	-	-	-	-	-	-	-	-	-	-1.52%	1.14%	1.35%	1.86%	1.29%	1.17%	2.12%	1.19%	1.16%	1.11%	1.15%	1.33%	1.23%	1.72%	2.54%	1.27%	1.08%	1.04%	0.97%	1.83%	1.96%

According to 2 Wall Street analysts, ADMA Biologics's projected average Quarter EPS for Dec 23 is $0.03, with a low estimate of $0.01 and a high estimate of $0.04. This represents a 119.30% increase compared to ADMA previous annual EPS of $0.01 (Sep 23).

ADMA Biologics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
FATE	Fate Therapeutics	$2.38	$39.75	1570.17%	Buy
ANTX	AN2 Therapeutics	$1.06	$8.75	725.47%	Buy
XFOR	X4 Pharmaceuticals	$0.59	$3.67	522.03%	Buy
INMB	INmune Bio	$5.66	$22.00	288.69%	Buy
ANEB	Anebulo Pharmaceuticals	$1.65	$6.00	263.64%	Buy
AKBA	Akebia Therapeutics	$1.95	$6.50	233.33%	Buy
PLRX	Pliant Therapeutics	$13.82	$39.71	187.34%	Buy
SANA	Sana Bio	$2.84	$8.00	181.69%	Buy
VXRT	Vaxart	$0.72	$2.00	177.78%	Hold
ETNB	89bio	$9.05	$22.00	143.09%	Buy
STOK	Stoke Therapeutics	$13.62	$30.60	124.67%	Buy
BCRX	BioCryst Pharmaceuticals	$7.82	$16.00	104.60%	Buy
RCUS	Arcus Biosciences	$16.77	$33.00	96.78%	Buy
MCRB	Seres Therapeutics	$0.66	$1.25	89.39%	Buy
CDTX	Cidara Therapeutics	$13.45	$24.00	78.44%	Buy
CRBU	Caribou Biosciences	$2.35	$3.00	27.66%	Buy
MDGL	Madrigal Pharmaceuticals	$339.04	$315.75	-6.87%	Buy
ATRA	Atara Biotherapeutics	$11.67	$10.50	-10.03%	Sell
ACLX	Arcellx	$100.48	$83.00	-17.40%	Buy
ADMA	ADMA Biologics	$21.78	$16.00	-26.54%	Strong Buy

ADMA Forecast FAQ

Is ADMA Biologics a good buy?

Yes, according to 2 Wall Street analysts, ADMA Biologics (ADMA) is considered a 'Strong Buy'. The rating consensus is based on 1 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of ADMA's total ratings.

What is ADMA's price target?

ADMA Biologics (ADMA) average price target is $16 with a range of $14 to $18, implying a -26.54% from its last price of $21.78. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ADMA Biologics stock go up soon?

According to Wall Street analysts' prediction for ADMA stock, the company can go down by -26.54% (from the last price of $21.78 to the average price target of $16), down by -17.36% based on the highest stock price target, and down by -35.72% based on the lowest stock price target.

Can ADMA Biologics stock reach $30?

ADMA's average twelve months analyst stock price target of $16 does not support the claim that ADMA Biologics can reach $30 in the near future.

What is ADMA Biologics's current price target trend?

1 Wall Street analyst forecast a $18 price target for ADMA Biologics (ADMA) this month, down -17.36% from its last price of $21.78. Compared to the last 3 and 12 months, the average price target decreased by -17.36% and decreased by -26.54%, respectively.

What are ADMA Biologics's analysts' financial forecasts?

ADMA Biologics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $382.9M (high $388.95M, low $378M), average EBITDA is $-182M (high $-179M, low $-185M), average net income is $80.34M (high $89.27M, low $72.39M), average SG&A $177.84M (high $180.5M, low $175.17M), and average EPS is $0.42 (high $0.452, low $0.393). ADMA's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $484.38M (high $499.84M, low $474.43M), average EBITDA is $-276M (high $-271M, low $-285M), average net income is $176.26M (high $187.7M, low $165.33M), average SG&A $274.02M (high $282.76M, low $268.39M), and average EPS is $0.72 (high $0.767, low $0.675).

Did the ADMA's actual financial results beat the analysts' financial forecasts?

Based on ADMA Biologics's last annual report (Dec 2023), the company's revenue was $258.22M, beating the average analysts forecast of $241.01M by 7.14%. Apple's EBITDA was $21.63M, missing the average prediction of $-116M by -118.64%. The company's net income was $-28.239M, beating the average estimation of $-11.481M by 145.96%. Apple's SG&A was $59.02M, missing the average forecast of $112.63M by -47.60%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.05 by -99.80%. In terms of the last quarterly report (Sep 2023), ADMA Biologics's revenue was $67.27M, beating the average analysts' forecast of $62.12M by 8.29%. The company's EBITDA was $8.69M, missing the average prediction of $-35.457M by -124.50%. ADMA Biologics's net income was $2.57M, missing the average estimation of $-1.836M by -239.71%. The company's SG&A was $14.73M, missing the average forecast of $35.14M by -58.10%. Lastly, the company's EPS was $0.0114, missing the average prediction of $-0.0075 by -252.00%